Compare The Coca-Cola Co K (KO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Twist Bioscience Corp — how do they compare? The Coca-Cola Co K trades at $82.07 (market cap $353.32B), while Twist Bioscience Corp trades at $94.75 (market cap $5.45B). The key difference: The Coca-Cola Co K is far larger — about 64.8× Twist Bioscience Corp's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| KO | TWST | |
|---|---|---|
Market Cap | $353.32B | $5.45B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $102.88 |
52-Week Low | $65.67 | $24.16 |
Enterprise Value | $383.39B | $5.37B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $82.05, up 0.6% with a bearish technical signal but strong fundamentals including 27.8% net margin and consistent earnings beats. Recent quarterly EPS exceeded expectations, while analyst consensus is bullish with a $90.67 price target. The company maintains robust cash flow and a 64-year dividend growth streak, supported by stable demand trends noted by Bank of America on April 10, 2026.
Outlook remains positive due to valuation upside and dividend reliability, though technical resistance near $83 and high debt levels pose risks. Investors benefit from defensive positioning amid market volatility, but must monitor regional demand fluctuations and interest rate impacts on borrowing costs.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
